AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03563144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 5-fluoro-2,4 (1H,3H)-pyrimidinedione
Study NCT03563144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
Study NCT03563144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin
Study NCT00612898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apricitabine
Description: 800mg BID apricitabine orally for 48 weeks
Study NCT00612898 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lamivudine
Description: 150mg BID lamivudine orally for 48 weeks
Study NCT03748043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactoferrin
Description: lactoferrin 100 mg per day plus ferric hydroxide polymaltose 6 mg /kilogram of Elemental iron
Study NCT03748043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Hydroxide Polymaltose
Description: group 2 will receive ferric hydroxide polymaltose 6 mg /kilogram of elemental iron
Study NCT01197443 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent-only Group
Description: Parent-only group will include the same skills and techniques to promote weight loss as given to the parent + child group, but the information will be delivered only to the parent. Parent group will be compared to the parent group of the parent + child treatment arm. The focus will be on implementing skills learned to assist the child in weight management. The treatment length is set for 12 weekly meetings and bi-monthly meetings during months 4 and 5. Each group session will be 60-min including weigh-ins. Group meetings focus on behavior change, weight loss, healthy eating and activity for the overweight child and parent.
Study NCT01197443 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent + Child Group
Description: The treatment for participants in the parent + child group will be administered in two separate groups, one for the parents and one for the child. Treatment will include the same skills and techniques to promote weight loss as given to the parent-only group, but the information will be delivered to both the parent and child. The treatment length, session schedule, treatment content and follow-up assessments are same as the parent-only group.
Study NCT02554279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: menotropin
Study NCT02554279 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant FSH
Study NCT00950261 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: tri-weekly cisplatin
Description: cisplatin 75mg/m2 every 3 weeks, intravenous, 3 cycles
Study NCT00475423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab [MabThera/Rituxan]
Description: 1000mg iv on days 1 and 15
Study NCT02385227 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exclusive blu™ e-cigarette A1
Description: Classic Tobacco rechargeable e cigarette
Study NCT02385227 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exclusive blu™ e-cigarette A2
Description: Magnificent Menthol rechargeable e cigarette
Study NCT02385227 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exclusive blu™ e-cigarette A3
Description: Cherry Crush rechargeable e cigarette
Study NCT02385227 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual blu™ e-cigarette and usual brand B1
Description: Classic Tobacco rechargeable e cigarette and a usual brand combustible cigarette
Study NCT02385227 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual blu™ e-cigarette and usual brand B2
Description: Magnificent Menthol rechargeable e cigarette and a usual brand combustible cigarette
Study NCT02385227 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual blu™ e-cigarette and usual brand B3
Description: Cherry Crush rechargeable e cigarette and a usual brand combustible cigarette
Study NCT02385227 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicotine product cessation C
Description: Nicotine cessation
Study NCT01133028 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral contingency management
Description: Teachers will learn to use reinforcements and response cost procedures to encourage children's display of prosocial behaviors.
Study NCT01133028 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral contingency management
Description: Teachers will learn to use reinforcements and response cost procedures to encourage children's display of prosocial behaviors.
Study NCT01133028 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tolerance training
Description: Teachers will be instructed in procedures to encourage the peer group to be accepting of children with ADHD.
Study NCT01492543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur Gimeracil Oteracil Potassium Capsule
Description: Aiyi® (Tegafur Gimeracil Oteracil Potassium Capsule; T25mg,G7.25mg,O24.5mg\*42 capsules/box), manufactured by Jiangsu Hengrui Medicine Co., Ltd.,
Study NCT01331018 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow harvest
Study NCT01331018 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC
Study NCT01331018 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Genetically Engineered Hematopoietic Stem Progenitor Cells
Description: Undergo infusion of genetically modified hematopoietic progenitor cell therapy
Study NCT01331018 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01331018 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Undergo leukapheresis
Study NCT01331018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Given IV
Study NCT01331018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Given SC
Study NCT01331018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO
Study NCT04133922 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GLP-1
Description: glucagon-like peptide 1
Study NCT04133922 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: we are using to replace basal insulin and to raise insulin concentrations during the insulin clamp
Study NCT04133922 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextrose 20 % in Water
Description: We are using Dextrose to maintain Euglycemia during the insulin clamp
Study NCT02537795 — intervention group
Intervention type: DEVICE
Intervention: deep brain stimulation
Description: Electrical stimulation of the anterior limb of the internal capsule or bed nucleus of the stria terminalis
Study NCT02537795 — intervention group
Intervention type: PROCEDURE
Intervention: anterior capsulotomy
Study NCT02330328 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Telemetry Monitoring
Study NCT02330328 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Telemetry Monitoring
Study NCT01687556 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: topical EGCG application on acne
Description: two times application of topical EGCG on acne lesion
Study NCT01687556 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: topical EGCG application on acne
Description: two times application of topical EGCG on acne lesion
Study NCT03657303 — intervention group
Intervention type: DEVICE
Intervention: Magnetic resonance imaging (MRI)
Description: Participants will undergo an initial (baseline) MR examination, followed by repeat MR examinations at approximately 1 month and 1 year following the baseline examination.
Study NCT02299778 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 13C6-p-aminobenzoic acid
Study NCT00991952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvocidib
Description: Given IV
Study NCT00991952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV
Study NCT00991952 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irinotecan hydrochloride
Description: Given IV
Study NCT00991952 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01517880 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be randomized to the placebo arm for the first 24 weeks of the study. Then, subjects in this arm will be re-randomized into either the 3,000 mg per day or 6,000 mg per day arm for the remaining 24 weeks of the study (total study duration 48 weeks).
Study NCT01978704 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adjustment of pre-prandial insulin doses on the bases of glycaemic load of the meal
Study NCT01978704 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adjustment of pre-prandial insulin doses on the bases of carbohydrates content of the meal
Study NCT02566720 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Amantadine
Description: Participants will initially receive amantadine at the starting dose of 50mg twice daily either by mouth or feeding tube. The dosage will increase every week by 50mg twice daily (100mg total dose increase) up to the target dose of 200mg twice daily. These are the usual doses and rate of increase that are offered to patients with brain injury.
Study NCT02566720 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: MRI Tractography Study
Description: Participants will initially receive a baseline MRI Tractography scan. The size of RAS fiber tracts will be measured prior to initiating treatment and near the time of discharge from the rehabilitation hospital or at approximately ninety-days.
Study NCT03010540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MORPHINE PLUS FENTANYL
Description: Effect Of Morphine Plus Fentanyl On Emergence Delirium
Study NCT03010540 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Effect Of Fentanyl Only On Emergence Delirium
Study NCT01871506 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Care (SC)
Description: 1. Initial counseling session: The initial counseling session will last approximately 45 minutes and will be conducted in-person or by phone by a tobacco treatment counselor. The session will be structured in a 5 As format and utilize Motivational Interviewing (MI) techniques.~2. 3 Weekly Follow-up Counseling Sessions: SC Patients will be offered 3 weekly proactive follow-up sessions, concentrated on quitting and staying quit throughout cancer treatment.~3. Medication advice: The tobacco counselor will advise SC subjects to use smoking cessation medication to assist with their quit. Smoking cessation medication will not be provided by the study free of cost for SC subjects.
Study NCT01871506 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Counseling (IC)
Description: The IC model includes all components of the SC as well as extended counseling support and up to 90 days of free FDA approved smoking cessation medication.~1. Extended counseling support: Participants in the IC group will be offered the same initial 4 counseling sessions as the SC group as well as 4 additional proactive biweekly sessions and 3 monthly booster sessions.~2. Smoking cessation medication: IC participants will be offered a 4-week supply of FDA-approved smoking cessation medication (varenicline, bupropion or nicotine replacement therapy) of their choice, with the option to renew the medication twice for up to 90 days of free medication. Participants are not required to take smoking cessation medication.
Study NCT01568723 — intervention group
Intervention type: GENETIC
Intervention: response to therapy
Description: evaluate specific markers for response to therapy at specific intervals pre and post therapy
Study NCT04379752 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cold-atmospeheric pressure plasma activated aqueous-alcohol solution treatment
Description: Cold plasma is generated and applied to carrier liquid. Subjects are provided with the liquid to apply to the treated area
Study NCT03006211 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nitrogen protoxide
Study NCT03006211 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Study NCT04475341 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS + Bone Marrow Aspirate Concentrate
Description: Both groups of patients are surgically treated with arthroscopic bone marrow stimulation (BMS). The control group will receive BMS alone but with a sham-treatment consisting of a Jamashidi (bone marrow aspiration) needle puncture of the iliac crest. The aspirated bone marrow concentrate will be collected and sent for cell characterisation but will not be inserted in the talar OCD. The intervention group will also receive arthroscopic BMS. From this group, BMAC from the iliac crest will be taken by the same needle puncture. Part of this concentrate will be sent for cell characterisation. Another part will be implanted into the talar OCD.
Study NCT04475341 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: BMS alone
Description: Both groups of patients are surgically treated with arthroscopic bone marrow stimulation (BMS). The control group will receive BMS alone but with a sham-treatment consisting of a Jamashidi (bone marrow aspiration) needle puncture of the iliac crest. The aspirated bone marrow concentrate will be collected and sent for cell characterisation but will not be inserted in the talar OCD. The intervention group will also receive arthroscopic BMS. From this group, BMAC from the iliac crest will be taken by the same needle puncture. Part of this concentrate will be sent for cell characterisation. Another part will be implanted into the talar OCD.
Study NCT04490629 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lyoplant Onlay
Description: Lyoplant Onlay is a kind of latest artificial Dura Mater
Study NCT04490629 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: DURAFORM
Description: DURAFORM is a kind of conventional artificial Dura Mater
Study NCT01028352 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Duloxetine
Description: Patients will be treated with open-label duloxetine:~* 30 mg daily x 7 days, then~* 60 mg daily x 3 weeks, then~* If a patient believes she has experienced a sufficient reduction in pain after 4 weeks of therapy, she will continue taking 60 mg daily for weeks 5-8~* If a patient does not believe she has experienced a sufficient reduction in pain after 4 weeks of therapy, she will have the option of increasing the dose to 60 mg twice daily for weeks 5-8.~* After completion of 8 weeks of therapy, patients who wish to discontinue therapy will taper off the drug over 1 week (50% decrease for 4 days, then additional 50% decrease for 3 days). Patients may continue therapy off-study at the discretion of their treating physician.
Study NCT03355027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80Mg Tablet
Description: Patients will be instructed to take once daily at night. Atorvastatin will be the preferred statin option for those with eGFR \< 60 ml/min/1.73m2. Patient may be required to complete a 4 week run-in period on a statin prior to entering the study (dependent on eligibility)
Study NCT03355027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 80Mg Tablet
Description: Patients will be instructed to take once daily at night. Atorvastatin will be the preferred statin option for those with eGFR \< 60 ml/min/1.73m2. Patient may be required to complete a 4 week run-in period on a statin prior to entering the study (dependent on eligibility)
Study NCT03355027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20Mg Tablet
Description: Patients will be instructed to take once daily at night. Rosuvastatin only to be prescribed if atorvastatin and simvastatin are not previously tolerated. Patient may be required to complete a 4 week run-in period on a statin prior to entering the study (dependent on eligibility)
Study NCT03355027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 20Mg Tablet
Description: Patients will be instructed to take once daily at night. Rosuvastatin only to be prescribed if atorvastatin and simvastatin are not previously tolerated. Patient may be required to complete a 4 week run-in period on a statin prior to entering the study (dependent on eligibility)
Study NCT03355027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40Mg Tablet
Description: Patients will be instructed to take once daily at night. Rosuvastatin only to be prescribed if atorvastatin and simvastatin are not previously tolerated. Patient may be required to complete a 4 week run-in period on a statin prior to entering the study (dependent on eligibility)
Study NCT03355027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 40Mg Tablet
Description: Patients will be instructed to take once daily at night. Rosuvastatin only to be prescribed if atorvastatin and simvastatin are not previously tolerated. Patient may be required to complete a 4 week run-in period on a statin prior to entering the study (dependent on eligibility)
Study NCT03355027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 80mg
Description: Patients will be instructed to take once daily at night. Patient may be required to complete a 4 week run-in period on a statin prior to entering the study (dependent on eligibility)
Study NCT02193061 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rotarix
Study NCT02193061 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RotaTeq
Study NCT00909610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodiol
Description: Ursodiol Tablets, 500 mg
Study NCT00909610 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Urso Forte™
Description: Urso Forte™ Tablets, 500 mg
Study NCT02597660 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Somatropin
Description: Active drug
Study NCT02813460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation H2 (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension with concentration 2 of sucralose (maximum 12 mg/mL) and best flavor 2 from session 1.
Study NCT04640727 — intervention group
Intervention type: PROCEDURE
Intervention: open reduction
Description: A sterile tourniquet is applied and an oblique posterolateral skin incision is made. Superficial dissection is carried out in the plane of the fracture hematoma until the distal lateral corner of the proximal fragment is identified. Once the metaphyseal side of the fracture has been identified, the dissection is carried across the joint to expose the medial articular surface. After exposure of the proximal fragment, the orientation of the distal fragment is defined and the soft tissues are sharply released off the anterior aspect of the distal fragment, with extension carried distally to the radial head. After irrigation and débridement of the fracture hematoma, the distal fragment is reduced with a towel clip. It is important to judge the reduction at the level of the articular surface rather than the metaphysis because plastic deformation or comminution of the metaphyseal fragment may be present. Pins (usually 0.062 inch) are placed percutaneously to secure the fracture.
Study NCT04640727 — intervention group
Intervention type: PROCEDURE
Intervention: closed reduction
Description: we applied a gentle varus force to the elbow while the patient was under general anesthesia, and we attempted to reposition the rotated fragment by directly pushing or by using Kirschner wires as joysticks . After repositioning, we applied gradual direct compression to the distal fracture fragment anteromedially.We then applied slight valgus force to the elbow with the forearm supinated and the elbow fully extended to maintain the reduction. After the fracture reduction was confifirmed to be within 2 mm, especially as seen on the anteroposterior, lateral radiographs,and internal obliquewe used smooth Kirschner wires to perform percutaneous pinning
Study NCT02597660 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bacteriostatic saline
Description: Placebo, the diluent used to reconstitute somatropin
Study NCT02597660 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Progressive exercise program
Description: Over a 12 week period beginning at the second study visit patients will perform a standard of care eccentric exercise training regime. Each session consists of three bilateral exercises: leg press, back squat, and hack squat. Subjects will complete four sets in each exercise with a 2-3 minute rest between sets. The repetitions/loads are: 15 repetition maximum (RM) week 1, 12RM weeks 2-3, 10RM weeks 4-5, 8RM weeks 6-8 and 6RM weeks 9-12. All exercises are performed from complete 0º to 90º of knee flexion and back again. Each of the eccentric and concentric phases will occur over a period of 3 seconds, respectively for a total of 6 seconds per contraction.
Study NCT02367846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined Oral Contraceptive (COC)
Description: The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral vs. non-oral ethinyl estradiol on net bone calcium balance. A prospective crossover study with repeated measures and a simple random assignment will be used to test the effects of 49 days of COC use on bone metabolism using 41Ca to determine net bone calcium balance. Subjects will be randomized to receive COC during either the first or second intervention period.